Diseases /
Malignant Solid Tumor
Back to Diseases List
Associated Genetic Biomarkers
Overview
Malignant solid tumors most frequently harbor alterations in TP53, KRAS, PIK3CA, APC, and CDKN2A [2].
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, KRAS Mutation, and KRAS Exon 2 Mutation are the most common alterations in malignant solid tumor [2].
Biomarker-Directed Therapies
Of the biomarker-directed therapies for malignant solid tumor, 3 are FDA-approved in at least one setting and 0 have NCCN guidelines in at least one setting [3].
Entrectinib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (FDA) |
| Note: Approved for patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, that are metastatic or unresectable, and that have progressed following treatment or have no satisfactory alternative therapy. |
Disease is predicted to be resistant: -
Larotrectinib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (FDA) |
| Note: Approved for patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, that are either metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory alternative treatments or whose cancer has progressed following treatment. |
Disease is predicted to be resistant: -
Pembrolizumab +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (FDA) |
| Note: FDA-approved for adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (FDA) |
| Note: Indicated for unresectable or metastatic tumor mutational burden-high [≥10 mutations/megabase] solid tumors with progression following prior treatment and no satisfactory alternative treatment options. |
Clinical Trials
There are 1252 clinical trials for malignant solid tumor, of which 960 are open and 292 are completed or closed. Of the trials that contain malignant solid tumor as an inclusion criterion, 6 are early phase 1 (6 open), 773 are phase 1 (563 open), 297 are phase 1/phase 2 (239 open), 160 are phase 2 (138 open), 2 are phase 3 (1 open), 4 are phase 4 (4 open), and 10 are no phase specified (9 open).
ERBB2, MSH2, and MLH1 are the most frequent gene inclusion criteria for malignant solid tumor clinical trials [3].
Pembrolizumab, nivolumab, and ipilimumab are the most common interventions in malignant solid tumor clinical trials.
Significant Genes in Malignant Solid Tumor
ABL1 +
ABL1 is altered in 1.79% of malignant solid tumor patients [2].
ABL1 is an inclusion eligibility criterion in 4 clinical trials for malignant solid tumor, of which 4 are open and 0 are closed. Of the trials that contain ABL1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].
ABL2 +
ABL2 is altered in 0.81% of malignant solid tumor patients [2].
ABL2 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains ABL2 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
ACBD5 +
ACBD5 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains ACBD5 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
ACVR1B +
ACVR1B is altered in 1.49% of malignant solid tumor patients [2].
ACVR1B is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains ACVR1B status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
AFAP1L2 +
AFAP1L2 is altered in 0.05% of malignant solid tumor patients [2].
AFAP1L2 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains AFAP1L2 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
AFF1 +
AFF1 is altered in 0.3% of malignant solid tumor patients [2].
AFF1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains AFF1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
AKT1 +
AKT1 is altered in 1.89% of malignant solid tumor patients [2].
AKT1 is an inclusion eligibility criterion in 27 clinical trials for malignant solid tumor, of which 21 are open and 6 are closed. Of the trials that contain AKT1 status and malignant solid tumor as inclusion criteria, 12 are phase 1 (7 open), 3 are phase 1/phase 2 (3 open), and 12 are phase 2 (11 open) [3].
AKT2 +
AKT2 is altered in 1.73% of malignant solid tumor patients [2].
AKT2 is an inclusion eligibility criterion in 22 clinical trials for malignant solid tumor, of which 17 are open and 5 are closed. Of the trials that contain AKT2 status and malignant solid tumor as inclusion criteria, 9 are phase 1 (5 open), 3 are phase 1/phase 2 (3 open), and 10 are phase 2 (9 open) [3].
AKT3 +
AKT3 is altered in 1.34% of malignant solid tumor patients [2].
AKT3 is an inclusion eligibility criterion in 22 clinical trials for malignant solid tumor, of which 17 are open and 5 are closed. Of the trials that contain AKT3 status and malignant solid tumor as inclusion criteria, 9 are phase 1 (5 open), 3 are phase 1/phase 2 (3 open), and 10 are phase 2 (9 open) [3].
ALK +
ALK is altered in 3.57% of malignant solid tumor patients [2].
ALK is an inclusion eligibility criterion in 30 clinical trials for malignant solid tumor, of which 23 are open and 7 are closed. Of the trials that contain ALK status and malignant solid tumor as inclusion criteria, 10 are phase 1 (6 open), 8 are phase 1/phase 2 (5 open), and 12 are phase 2 (12 open) [3].
APC +
APC is altered in 11.81% of malignant solid tumor patients [2].
APC is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains APC status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
APH1A +
APH1A is altered in 0.64% of malignant solid tumor patients [2].
APH1A is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains APH1A status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
APOBEC3A +
APOBEC3A is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3A status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
APOBEC3B +
APOBEC3B is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3B status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
APOBEC3C +
APOBEC3C is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3C status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
APOBEC3D +
APOBEC3D is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3D status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
APOBEC3G +
APOBEC3G is altered in 1.11% of malignant solid tumor patients [2].
APOBEC3G is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3G status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
APOBEC3H +
APOBEC3H is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3H status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
ARAF +
ARAF is altered in 1.6% of malignant solid tumor patients [2].
ARAF is an inclusion eligibility criterion in 17 clinical trials for malignant solid tumor, of which 14 are open and 3 are closed. Of the trials that contain ARAF status and malignant solid tumor as inclusion criteria, 10 are phase 1 (9 open), 2 are phase 1/phase 2 (2 open), and 5 are phase 2 (3 open) [3].
ARID1A +
ARID1A is altered in 9.46% of malignant solid tumor patients [2].
ARID1A is an inclusion eligibility criterion in 18 clinical trials for malignant solid tumor, of which 15 are open and 3 are closed. Of the trials that contain ARID1A status and malignant solid tumor as inclusion criteria, 10 are phase 1 (9 open), 5 are phase 1/phase 2 (3 open), and 3 are phase 2 (3 open) [3].
ASXL1 +
ASXL1 is altered in 3.73% of malignant solid tumor patients [2].
ASXL1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains ASXL1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
ATM +
ATM is altered in 5.8% of malignant solid tumor patients [2].
ATM is an inclusion eligibility criterion in 44 clinical trials for malignant solid tumor, of which 37 are open and 7 are closed. Of the trials that contain ATM status and malignant solid tumor as inclusion criteria, 17 are phase 1 (13 open), 8 are phase 1/phase 2 (5 open), and 19 are phase 2 (19 open) [3].
ATR +
ATR is altered in 3.15% of malignant solid tumor patients [2].
ATR is an inclusion eligibility criterion in 30 clinical trials for malignant solid tumor, of which 24 are open and 6 are closed. Of the trials that contain ATR status and malignant solid tumor as inclusion criteria, 12 are phase 1 (9 open), 8 are phase 1/phase 2 (5 open), and 10 are phase 2 (10 open) [3].
ATRX +
ATRX is altered in 5.72% of malignant solid tumor patients [2].
ATRX is an inclusion eligibility criterion in 16 clinical trials for malignant solid tumor, of which 14 are open and 2 are closed. Of the trials that contain ATRX status and malignant solid tumor as inclusion criteria, 9 are phase 1 (9 open), 4 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [3].
AXL +
AXL is altered in 2.2% of malignant solid tumor patients [2].
AXL is an inclusion eligibility criterion in 4 clinical trials for malignant solid tumor, of which 3 are open and 1 is closed. Of the trials that contain AXL status and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 2 (2 open) [3].
BAP1 +
BAP1 is altered in 2.57% of malignant solid tumor patients [2].
BAP1 is an inclusion eligibility criterion in 3 clinical trials for malignant solid tumor, of which 3 are open and 0 are closed. Of the trials that contain BAP1 status and malignant solid tumor as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
BARD1 +
BARD1 is altered in 1.56% of malignant solid tumor patients [2].
BARD1 is an inclusion eligibility criterion in 32 clinical trials for malignant solid tumor, of which 26 are open and 6 are closed. Of the trials that contain BARD1 status and malignant solid tumor as inclusion criteria, 14 are phase 1 (11 open), 7 are phase 1/phase 2 (4 open), and 11 are phase 2 (11 open) [3].
BCL2 +
BCL2 is altered in 0.61% of malignant solid tumor patients [2].
BCL2 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains BCL2 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
BCR +
BCR is altered in 1.41% of malignant solid tumor patients [2].
BCR is an inclusion eligibility criterion in 3 clinical trials for malignant solid tumor, of which 3 are open and 0 are closed. Of the trials that contain BCR status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].
BLM +
BLM is altered in 2.22% of malignant solid tumor patients [2].
BLM is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 1 is open and 1 is closed. Of the trials that contain BLM status and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open) [3].
BRAF +
BRAF is altered in 6.59% of malignant solid tumor patients [2].
BRAF is an inclusion eligibility criterion in 69 clinical trials for malignant solid tumor, of which 49 are open and 20 are closed. Of the trials that contain BRAF status and malignant solid tumor as inclusion criteria, 36 are phase 1 (21 open), 11 are phase 1/phase 2 (10 open), and 22 are phase 2 (18 open) [3].
BRCA1 +
BRCA1 is altered in 3.21% of malignant solid tumor patients [2].
BRCA1 is an inclusion eligibility criterion in 54 clinical trials for malignant solid tumor, of which 43 are open and 11 are closed. Of the trials that contain BRCA1 status and malignant solid tumor as inclusion criteria, 24 are phase 1 (18 open), 12 are phase 1/phase 2 (7 open), and 18 are phase 2 (18 open) [3].
BRCA2 +
BRCA2 is altered in 5.45% of malignant solid tumor patients [2].
BRCA2 is an inclusion eligibility criterion in 54 clinical trials for malignant solid tumor, of which 43 are open and 11 are closed. Of the trials that contain BRCA2 status and malignant solid tumor as inclusion criteria, 24 are phase 1 (18 open), 12 are phase 1/phase 2 (7 open), and 18 are phase 2 (18 open) [3].
BRD3 +
BRD3 is altered in 2.41% of malignant solid tumor patients [2].
BRD3 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains BRD3 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
BRD4 +
BRD4 is altered in 2.6% of malignant solid tumor patients [2].
BRD4 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains BRD4 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
BRIP1 +
BRIP1 is altered in 2.82% of malignant solid tumor patients [2].
BRIP1 is an inclusion eligibility criterion in 33 clinical trials for malignant solid tumor, of which 27 are open and 6 are closed. Of the trials that contain BRIP1 status and malignant solid tumor as inclusion criteria, 15 are phase 1 (12 open), 7 are phase 1/phase 2 (4 open), and 11 are phase 2 (11 open) [3].
BTRC +
BTRC is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains BTRC status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
C11ORF30 +
C11orf30 is altered in 0.52% of malignant solid tumor patients [2].
C11orf30 is an inclusion eligibility criterion in 12 clinical trials for malignant solid tumor, of which 10 are open and 2 are closed. Of the trials that contain C11orf30 status and malignant solid tumor as inclusion criteria, 6 are phase 1 (6 open), 4 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [3].
CCDC6 +
CCDC6 is altered in 0.29% of malignant solid tumor patients [2].
CCDC6 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains CCDC6 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
CCNA1 +
CCNA1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains CCNA1 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
CCNA2 +
CCNA2 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains CCNA2 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
CCNB1 +
CCNB1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains CCNB1 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
CCNB2 +
CCNB2 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains CCNB2 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
CCNB3 +
CCNB3 is altered in 0.03% of malignant solid tumor patients [2].
CCNB3 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains CCNB3 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
CCND1 +
CCND1 is altered in 4.48% of malignant solid tumor patients [2].
CCND1 is an inclusion eligibility criterion in 12 clinical trials for malignant solid tumor, of which 11 are open and 1 is closed. Of the trials that contain CCND1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 10 are phase 2 (9 open) [3].
CCND2 +
CCND2 is altered in 1.51% of malignant solid tumor patients [2].
CCND2 is an inclusion eligibility criterion in 8 clinical trials for malignant solid tumor, of which 7 are open and 1 is closed. Of the trials that contain CCND2 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 7 are phase 2 (6 open) [3].
CCND3 +
CCND3 is altered in 1.04% of malignant solid tumor patients [2].
CCND3 is an inclusion eligibility criterion in 8 clinical trials for malignant solid tumor, of which 7 are open and 1 is closed. Of the trials that contain CCND3 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 7 are phase 2 (6 open) [3].
CCNE1 +
CCNE1 is altered in 2.41% of malignant solid tumor patients [2].
CCNE1 is an inclusion eligibility criterion in 11 clinical trials for malignant solid tumor, of which 7 are open and 4 are closed. Of the trials that contain CCNE1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 9 are phase 2 (6 open) [3].
CCNE2 +
CCNE2 is an inclusion eligibility criterion in 4 clinical trials for malignant solid tumor, of which 3 are open and 1 is closed. Of the trials that contain CCNE2 status and malignant solid tumor as inclusion criteria, 4 are phase 2 (3 open) [3].
CD274 +
CD274 is altered in 0.98% of malignant solid tumor patients [2].
CD274 is an inclusion eligibility criterion in 3 clinical trials for malignant solid tumor, of which 3 are open and 0 are closed. Of the trials that contain CD274 status and malignant solid tumor as inclusion criteria, 3 are phase 2 (3 open) [3].
CDH1 +
CDH1 is altered in 3.41% of malignant solid tumor patients [2].
CDH1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains CDH1 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
CDK1 +
CDK1 is altered in 0.81% of malignant solid tumor patients [2].
CDK1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains CDK1 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
CDK12 +
CDK12 is altered in 3.83% of malignant solid tumor patients [2].
CDK12 is an inclusion eligibility criterion in 34 clinical trials for malignant solid tumor, of which 27 are open and 7 are closed. Of the trials that contain CDK12 status and malignant solid tumor as inclusion criteria, 15 are phase 1 (11 open), 7 are phase 1/phase 2 (4 open), and 12 are phase 2 (12 open) [3].
CDK2 +
CDK2 is altered in 0.17% of malignant solid tumor patients [2].
CDK2 is an inclusion eligibility criterion in 4 clinical trials for malignant solid tumor, of which 3 are open and 1 is closed. Of the trials that contain CDK2 status and malignant solid tumor as inclusion criteria, 4 are phase 2 (3 open) [3].
CDK4 +
CDK4 is altered in 2.46% of malignant solid tumor patients [2].
CDK4 is an inclusion eligibility criterion in 12 clinical trials for malignant solid tumor, of which 11 are open and 1 is closed. Of the trials that contain CDK4 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 10 are phase 2 (9 open) [3].
CDK6 +
CDK6 is altered in 1.01% of malignant solid tumor patients [2].
CDK6 is an inclusion eligibility criterion in 11 clinical trials for malignant solid tumor, of which 10 are open and 1 is closed. Of the trials that contain CDK6 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 10 are phase 2 (9 open) [3].
CDKN1A +
CDKN1A is altered in 0.96% of malignant solid tumor patients [2].
CDKN1A is an inclusion eligibility criterion in 5 clinical trials for malignant solid tumor, of which 3 are open and 2 are closed. Of the trials that contain CDKN1A status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) and 4 are phase 2 (3 open) [3].
CDKN1B +
CDKN1B is altered in 1.96% of malignant solid tumor patients [2].
CDKN1B is an inclusion eligibility criterion in 4 clinical trials for malignant solid tumor, of which 2 are open and 2 are closed. Of the trials that contain CDKN1B status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (2 open) [3].
CDKN2A +
CDKN2A is altered in 11.23% of malignant solid tumor patients [2].
CDKN2A is an inclusion eligibility criterion in 14 clinical trials for malignant solid tumor, of which 10 are open and 4 are closed. Of the trials that contain CDKN2A status and malignant solid tumor as inclusion criteria, 4 are phase 1 (1 open) and 10 are phase 2 (9 open) [3].
CDKN2B +
CDKN2B is altered in 7.98% of malignant solid tumor patients [2].
CDKN2B is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains CDKN2B status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
CEP43 +
CEP43 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains CEP43 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
CHD4 +
CHD4 is altered in 3.84% of malignant solid tumor patients [2].
CHD4 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains CHD4 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
CHEK1 +
CHEK1 is altered in 0.84% of malignant solid tumor patients [2].
CHEK1 is an inclusion eligibility criterion in 29 clinical trials for malignant solid tumor, of which 24 are open and 5 are closed. Of the trials that contain CHEK1 status and malignant solid tumor as inclusion criteria, 13 are phase 1 (11 open), 7 are phase 1/phase 2 (4 open), and 9 are phase 2 (9 open) [3].
CHEK2 +
CHEK2 is altered in 1.63% of malignant solid tumor patients [2].
CHEK2 is an inclusion eligibility criterion in 32 clinical trials for malignant solid tumor, of which 26 are open and 6 are closed. Of the trials that contain CHEK2 status and malignant solid tumor as inclusion criteria, 14 are phase 1 (11 open), 7 are phase 1/phase 2 (4 open), and 11 are phase 2 (11 open) [3].
CRKL +
CRKL is altered in 0.91% of malignant solid tumor patients [2].
CRKL is an inclusion eligibility criterion in 25 clinical trials for malignant solid tumor, of which 20 are open and 5 are closed. Of the trials that contain CRKL status and malignant solid tumor as inclusion criteria, 14 are phase 1 (11 open), 4 are phase 1/phase 2 (4 open), and 7 are phase 2 (5 open) [3].
CSF1R +
CSF1R is altered in 1.53% of malignant solid tumor patients [2].
CSF1R is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain CSF1R status and malignant solid tumor as inclusion criteria, 2 are phase 2 (2 open) [3].
CTNNB1 +
CTNNB1 is altered in 3.34% of malignant solid tumor patients [2].
CTNNB1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains CTNNB1 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
CYLD +
CYLD is altered in 1.74% of malignant solid tumor patients [2].
CYLD is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains CYLD status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
DAXX +
DAXX is altered in 1.57% of malignant solid tumor patients [2].
DAXX is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains DAXX status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
DDIT3 +
DDIT3 is altered in 0.16% of malignant solid tumor patients [2].
DDIT3 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains DDIT3 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
DDR2 +
DDR2 is altered in 2.18% of malignant solid tumor patients [2].
DDR2 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 1 is open and 1 is closed. Of the trials that contain DDR2 status and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open) [3].
DEK +
DEK is altered in 1.13% of malignant solid tumor patients [2].
DEK is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains DEK status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
DICER1 +
DICER1 is altered in 2.55% of malignant solid tumor patients [2].
DICER1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains DICER1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
DLL4 +
DLL4 is altered in 0.0% of malignant solid tumor patients [2].
DLL4 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains DLL4 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
DNMT3A +
DNMT3A is altered in 2.49% of malignant solid tumor patients [2].
DNMT3A is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains DNMT3A status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
DVL1 +
DVL1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains DVL1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
EGFR +
EGFR is altered in 7.61% of malignant solid tumor patients [2].
EGFR is an inclusion eligibility criterion in 39 clinical trials for malignant solid tumor, of which 29 are open and 10 are closed. Of the trials that contain EGFR status and malignant solid tumor as inclusion criteria, 14 are phase 1 (9 open), 12 are phase 1/phase 2 (8 open), and 13 are phase 2 (12 open) [3].
ELL +
ELL is altered in 0.08% of malignant solid tumor patients [2].
ELL is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains ELL status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
EPCAM +
EPCAM is altered in 0.6% of malignant solid tumor patients [2].
EPCAM is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain EPCAM status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
ERBB2 +
ERBB2 is altered in 5.44% of malignant solid tumor patients [2].
ERBB2 is an inclusion eligibility criterion in 90 clinical trials for malignant solid tumor, of which 66 are open and 24 are closed. Of the trials that contain ERBB2 status and malignant solid tumor as inclusion criteria, 51 are phase 1 (37 open), 19 are phase 1/phase 2 (11 open), and 20 are phase 2 (18 open) [3].
ERBB3 +
ERBB3 is altered in 3.19% of malignant solid tumor patients [2].
ERBB3 is an inclusion eligibility criterion in 7 clinical trials for malignant solid tumor, of which 6 are open and 1 is closed. Of the trials that contain ERBB3 status and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [3].
ERBB4 +
ERBB4 is altered in 3.41% of malignant solid tumor patients [2].
ERBB4 is an inclusion eligibility criterion in 4 clinical trials for malignant solid tumor, of which 3 are open and 1 is closed. Of the trials that contain ERBB4 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
ERC1 +
ERC1 is altered in 0.08% of malignant solid tumor patients [2].
ERC1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains ERC1 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
ERCC1 +
ERCC1 is altered in 0.23% of malignant solid tumor patients [2].
ERCC1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains ERCC1 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
ERCC2 +
ERCC2 is altered in 2.06% of malignant solid tumor patients [2].
ERCC2 is an inclusion eligibility criterion in 11 clinical trials for malignant solid tumor, of which 9 are open and 2 are closed. Of the trials that contain ERCC2 status and malignant solid tumor as inclusion criteria, 6 are phase 1 (6 open), 4 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].
ERCC3 +
ERCC3 is altered in 1.23% of malignant solid tumor patients [2].
ERCC3 is an inclusion eligibility criterion in 11 clinical trials for malignant solid tumor, of which 9 are open and 2 are closed. Of the trials that contain ERCC3 status and malignant solid tumor as inclusion criteria, 6 are phase 1 (6 open), 4 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].
ERCC4 +
ERCC4 is altered in 1.65% of malignant solid tumor patients [2].
ERCC4 is an inclusion eligibility criterion in 11 clinical trials for malignant solid tumor, of which 9 are open and 2 are closed. Of the trials that contain ERCC4 status and malignant solid tumor as inclusion criteria, 6 are phase 1 (6 open), 4 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].
ERCC5 +
ERCC5 is altered in 2.18% of malignant solid tumor patients [2].
ERCC5 is an inclusion eligibility criterion in 11 clinical trials for malignant solid tumor, of which 9 are open and 2 are closed. Of the trials that contain ERCC5 status and malignant solid tumor as inclusion criteria, 6 are phase 1 (6 open), 4 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].
ERCC6 +
ERCC6 is altered in 0.91% of malignant solid tumor patients [2].
ERCC6 is an inclusion eligibility criterion in 11 clinical trials for malignant solid tumor, of which 9 are open and 2 are closed. Of the trials that contain ERCC6 status and malignant solid tumor as inclusion criteria, 6 are phase 1 (6 open), 4 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].
ETV6 +
ETV6 is altered in 2.2% of malignant solid tumor patients [2].
ETV6 is an inclusion eligibility criterion in 3 clinical trials for malignant solid tumor, of which 3 are open and 0 are closed. Of the trials that contain ETV6 status and malignant solid tumor as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [3].
EWSR1 +
EWSR1 is altered in 1.06% of malignant solid tumor patients [2].
EWSR1 is an inclusion eligibility criterion in 4 clinical trials for malignant solid tumor, of which 4 are open and 0 are closed. Of the trials that contain EWSR1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 1/phase 2 (3 open) [3].
EXO1 +
EXO1 is altered in 2.5% of malignant solid tumor patients [2].
EXO1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains EXO1 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
EZH2 +
EZH2 is altered in 1.19% of malignant solid tumor patients [2].
EZH2 is an inclusion eligibility criterion in 5 clinical trials for malignant solid tumor, of which 4 are open and 1 is closed. Of the trials that contain EZH2 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].
FAM175A +
FAM175A is altered in 0.54% of malignant solid tumor patients [2].
FAM175A is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FAM175A status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
FANCA +
FANCA is altered in 2.82% of malignant solid tumor patients [2].
FANCA is an inclusion eligibility criterion in 33 clinical trials for malignant solid tumor, of which 27 are open and 6 are closed. Of the trials that contain FANCA status and malignant solid tumor as inclusion criteria, 14 are phase 1 (11 open), 7 are phase 1/phase 2 (4 open), and 12 are phase 2 (12 open) [3].
FANCB +
FANCB is altered in 1.71% of malignant solid tumor patients [2].
FANCB is an inclusion eligibility criterion in 27 clinical trials for malignant solid tumor, of which 22 are open and 5 are closed. Of the trials that contain FANCB status and malignant solid tumor as inclusion criteria, 11 are phase 1 (9 open), 7 are phase 1/phase 2 (4 open), and 9 are phase 2 (9 open) [3].
FANCC +
FANCC is altered in 1.04% of malignant solid tumor patients [2].
FANCC is an inclusion eligibility criterion in 27 clinical trials for malignant solid tumor, of which 22 are open and 5 are closed. Of the trials that contain FANCC status and malignant solid tumor as inclusion criteria, 11 are phase 1 (9 open), 7 are phase 1/phase 2 (4 open), and 9 are phase 2 (9 open) [3].
FANCD2 +
FANCD2 is altered in 5.03% of malignant solid tumor patients [2].
FANCD2 is an inclusion eligibility criterion in 27 clinical trials for malignant solid tumor, of which 22 are open and 5 are closed. Of the trials that contain FANCD2 status and malignant solid tumor as inclusion criteria, 11 are phase 1 (9 open), 7 are phase 1/phase 2 (4 open), and 9 are phase 2 (9 open) [3].
FANCE +
FANCE is altered in 1.49% of malignant solid tumor patients [2].
FANCE is an inclusion eligibility criterion in 27 clinical trials for malignant solid tumor, of which 22 are open and 5 are closed. Of the trials that contain FANCE status and malignant solid tumor as inclusion criteria, 11 are phase 1 (9 open), 7 are phase 1/phase 2 (4 open), and 9 are phase 2 (9 open) [3].
FANCF +
FANCF is altered in 1.03% of malignant solid tumor patients [2].
FANCF is an inclusion eligibility criterion in 27 clinical trials for malignant solid tumor, of which 22 are open and 5 are closed. Of the trials that contain FANCF status and malignant solid tumor as inclusion criteria, 11 are phase 1 (9 open), 7 are phase 1/phase 2 (4 open), and 9 are phase 2 (9 open) [3].
FANCG +
FANCG is altered in 1.45% of malignant solid tumor patients [2].
FANCG is an inclusion eligibility criterion in 27 clinical trials for malignant solid tumor, of which 22 are open and 5 are closed. Of the trials that contain FANCG status and malignant solid tumor as inclusion criteria, 11 are phase 1 (9 open), 7 are phase 1/phase 2 (4 open), and 9 are phase 2 (9 open) [3].
FANCI +
FANCI is altered in 2.88% of malignant solid tumor patients [2].
FANCI is an inclusion eligibility criterion in 27 clinical trials for malignant solid tumor, of which 22 are open and 5 are closed. Of the trials that contain FANCI status and malignant solid tumor as inclusion criteria, 11 are phase 1 (9 open), 7 are phase 1/phase 2 (4 open), and 9 are phase 2 (9 open) [3].
FANCL +
FANCL is altered in 1.25% of malignant solid tumor patients [2].
FANCL is an inclusion eligibility criterion in 29 clinical trials for malignant solid tumor, of which 24 are open and 5 are closed. Of the trials that contain FANCL status and malignant solid tumor as inclusion criteria, 13 are phase 1 (11 open), 7 are phase 1/phase 2 (4 open), and 9 are phase 2 (9 open) [3].
FANCM +
FANCM is altered in 5.24% of malignant solid tumor patients [2].
FANCM is an inclusion eligibility criterion in 27 clinical trials for malignant solid tumor, of which 22 are open and 5 are closed. Of the trials that contain FANCM status and malignant solid tumor as inclusion criteria, 11 are phase 1 (9 open), 7 are phase 1/phase 2 (4 open), and 9 are phase 2 (9 open) [3].
FBXW7 +
FBXW7 is altered in 3.82% of malignant solid tumor patients [2].
FBXW7 is an inclusion eligibility criterion in 5 clinical trials for malignant solid tumor, of which 4 are open and 1 is closed. Of the trials that contain FBXW7 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) and 4 are phase 2 (4 open) [3].
FGF1 +
FGF1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FGF1 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF10 +
FGF10 is altered in 1.39% of malignant solid tumor patients [2].
FGF10 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FGF10 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF11 +
FGF11 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FGF11 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF12 +
FGF12 is altered in 0.02% of malignant solid tumor patients [2].
FGF12 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FGF12 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF13 +
FGF13 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FGF13 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF14 +
FGF14 is altered in 0.41% of malignant solid tumor patients [2].
FGF14 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FGF14 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF16 +
FGF16 is altered in 0.0% of malignant solid tumor patients [2].
FGF16 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FGF16 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF17 +
FGF17 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FGF17 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF18 +
FGF18 is altered in 0.01% of malignant solid tumor patients [2].
FGF18 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FGF18 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF19 +
FGF19 is altered in 4.49% of malignant solid tumor patients [2].
FGF19 is an inclusion eligibility criterion in 3 clinical trials for malignant solid tumor, of which 2 are open and 1 is closed. Of the trials that contain FGF19 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 1/phase 2 (2 open) [3].
FGF2 +
FGF2 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FGF2 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF20 +
FGF20 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FGF20 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF21 +
FGF21 is altered in 0.0% of malignant solid tumor patients [2].
FGF21 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FGF21 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF22 +
FGF22 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FGF22 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF23 +
FGF23 is altered in 1.5% of malignant solid tumor patients [2].
FGF23 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FGF23 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF3 +
FGF3 is altered in 4.51% of malignant solid tumor patients [2].
FGF3 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FGF3 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF4 +
FGF4 is altered in 4.37% of malignant solid tumor patients [2].
FGF4 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 1 is open and 1 is closed. Of the trials that contain FGF4 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [3].
FGF5 +
FGF5 is altered in 0.82% of malignant solid tumor patients [2].
FGF5 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FGF5 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF6 +
FGF6 is altered in 1.63% of malignant solid tumor patients [2].
FGF6 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FGF6 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF7 +
FGF7 is altered in 0.82% of malignant solid tumor patients [2].
FGF7 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FGF7 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF8 +
FGF8 is altered in 0.01% of malignant solid tumor patients [2].
FGF8 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FGF8 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF9 +
FGF9 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain FGF9 status and malignant solid tumor as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGFR1 +
FGFR1 is altered in 3.94% of malignant solid tumor patients [2].
FGFR1 is an inclusion eligibility criterion in 25 clinical trials for malignant solid tumor, of which 19 are open and 6 are closed. Of the trials that contain FGFR1 status and malignant solid tumor as inclusion criteria, 6 are phase 1 (1 open), 6 are phase 1/phase 2 (5 open), 12 are phase 2 (12 open), and 1 is phase 4 (1 open) [3].
FGFR2 +
FGFR2 is altered in 2.22% of malignant solid tumor patients [2].
FGFR2 is an inclusion eligibility criterion in 31 clinical trials for malignant solid tumor, of which 23 are open and 8 are closed. Of the trials that contain FGFR2 status and malignant solid tumor as inclusion criteria, 9 are phase 1 (2 open), 6 are phase 1/phase 2 (5 open), 12 are phase 2 (12 open), 1 is phase 4 (1 open), and 3 are no phase specified (3 open) [3].
FGFR3 +
FGFR3 is altered in 2.65% of malignant solid tumor patients [2].
FGFR3 is an inclusion eligibility criterion in 25 clinical trials for malignant solid tumor, of which 18 are open and 7 are closed. Of the trials that contain FGFR3 status and malignant solid tumor as inclusion criteria, 7 are phase 1 (1 open), 5 are phase 1/phase 2 (4 open), 12 are phase 2 (12 open), and 1 is phase 4 (1 open) [3].
FGFR4 +
FGFR4 is altered in 1.92% of malignant solid tumor patients [2].
FGFR4 is an inclusion eligibility criterion in 13 clinical trials for malignant solid tumor, of which 10 are open and 3 are closed. Of the trials that contain FGFR4 status and malignant solid tumor as inclusion criteria, 3 are phase 1 (1 open), 4 are phase 1/phase 2 (3 open), 5 are phase 2 (5 open), and 1 is phase 4 (1 open) [3].
FIGF +
FIGF is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FIGF status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
FLCN +
FLCN is altered in 1.61% of malignant solid tumor patients [2].
FLCN is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FLCN status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
FLI1 +
FLI1 is altered in 0.27% of malignant solid tumor patients [2].
FLI1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FLI1 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FLT1 +
FLT1 is altered in 3.43% of malignant solid tumor patients [2].
FLT1 is an inclusion eligibility criterion in 5 clinical trials for malignant solid tumor, of which 4 are open and 1 is closed. Of the trials that contain FLT1 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 4 are phase 2 (3 open) [3].
FLT3 +
FLT3 is altered in 2.42% of malignant solid tumor patients [2].
FLT3 is an inclusion eligibility criterion in 6 clinical trials for malignant solid tumor, of which 4 are open and 2 are closed. Of the trials that contain FLT3 status and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open) and 4 are phase 2 (3 open) [3].
FLT4 +
FLT4 is altered in 3.34% of malignant solid tumor patients [2].
FLT4 is an inclusion eligibility criterion in 4 clinical trials for malignant solid tumor, of which 3 are open and 1 is closed. Of the trials that contain FLT4 status and malignant solid tumor as inclusion criteria, 4 are phase 2 (3 open) [3].
FOXO1 +
FOXO1 is altered in 1.11% of malignant solid tumor patients [2].
FOXO1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FOXO1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD1 +
FZD1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FZD1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD10 +
FZD10 is altered in 0.01% of malignant solid tumor patients [2].
FZD10 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FZD10 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD2 +
FZD2 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FZD2 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD3 +
FZD3 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FZD3 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD4 +
FZD4 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FZD4 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD5 +
FZD5 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FZD5 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD6 +
FZD6 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FZD6 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD7 +
FZD7 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FZD7 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD8 +
FZD8 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FZD8 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD9 +
FZD9 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FZD9 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
GATA3 +
GATA3 is altered in 4.02% of malignant solid tumor patients [2].
GATA3 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains GATA3 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
GNA11 +
GNA11 is altered in 0.95% of malignant solid tumor patients [2].
GNA11 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains GNA11 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
GNAQ +
GNAQ is altered in 0.73% of malignant solid tumor patients [2].
GNAQ is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains GNAQ status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
GOLGA5 +
GOLGA5 is altered in 0.12% of malignant solid tumor patients [2].
GOLGA5 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains GOLGA5 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
HDAC1 +
HDAC1 is altered in 0.76% of malignant solid tumor patients [2].
HDAC1 is an inclusion eligibility criterion in 12 clinical trials for malignant solid tumor, of which 10 are open and 2 are closed. Of the trials that contain HDAC1 status and malignant solid tumor as inclusion criteria, 6 are phase 1 (6 open), 4 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [3].
HDAC2 +
HDAC2 is altered in 0.01% of malignant solid tumor patients [2].
HDAC2 is an inclusion eligibility criterion in 12 clinical trials for malignant solid tumor, of which 10 are open and 2 are closed. Of the trials that contain HDAC2 status and malignant solid tumor as inclusion criteria, 6 are phase 1 (6 open), 4 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [3].
HGF +
HGF is altered in 2.43% of malignant solid tumor patients [2].
HGF is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains HGF status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
HOOK3 +
HOOK3 is altered in 0.11% of malignant solid tumor patients [2].
HOOK3 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains HOOK3 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
HRAS +
HRAS is altered in 1.02% of malignant solid tumor patients [2].
HRAS is an inclusion eligibility criterion in 27 clinical trials for malignant solid tumor, of which 19 are open and 8 are closed. Of the trials that contain HRAS status and malignant solid tumor as inclusion criteria, 15 are phase 1 (10 open), 5 are phase 1/phase 2 (3 open), and 7 are phase 2 (6 open) [3].
IDH1 +
IDH1 is altered in 2.96% of malignant solid tumor patients [2].
IDH1 is an inclusion eligibility criterion in 14 clinical trials for malignant solid tumor, of which 12 are open and 2 are closed. Of the trials that contain IDH1 status and malignant solid tumor as inclusion criteria, 7 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), and 6 are phase 2 (6 open) [3].
IDH2 +
IDH2 is altered in 1.02% of malignant solid tumor patients [2].
IDH2 is an inclusion eligibility criterion in 8 clinical trials for malignant solid tumor, of which 6 are open and 2 are closed. Of the trials that contain IDH2 status and malignant solid tumor as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 4 are phase 2 (4 open) [3].
INPP4A +
INPP4A is altered in 1.38% of malignant solid tumor patients [2].
INPP4A is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains INPP4A status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
INPP4B +
INPP4B is altered in 1.41% of malignant solid tumor patients [2].
INPP4B is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains INPP4B status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
INPP5D +
INPP5D is altered in 0.12% of malignant solid tumor patients [2].
INPP5D is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains INPP5D status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
INPPL1 +
INPPL1 is altered in 3.47% of malignant solid tumor patients [2].
INPPL1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains INPPL1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
IRS2 +
IRS2 is altered in 3.16% of malignant solid tumor patients [2].
IRS2 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains IRS2 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
JAG1 +
JAG1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains JAG1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
JAK1 +
JAK1 is altered in 2.02% of malignant solid tumor patients [2].
JAK1 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 1 is open and 1 is closed. Of the trials that contain JAK1 status and malignant solid tumor as inclusion criteria, 2 are phase 2 (1 open) [3].
JAK2 +
JAK2 is altered in 2.01% of malignant solid tumor patients [2].
JAK2 is an inclusion eligibility criterion in 3 clinical trials for malignant solid tumor, of which 1 is open and 2 are closed. Of the trials that contain JAK2 status and malignant solid tumor as inclusion criteria, 3 are phase 2 (1 open) [3].
JAK3 +
JAK3 is altered in 2.04% of malignant solid tumor patients [2].
JAK3 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 1 is open and 1 is closed. Of the trials that contain JAK3 status and malignant solid tumor as inclusion criteria, 2 are phase 2 (1 open) [3].
KDM6A +
KDM6A is altered in 3.73% of malignant solid tumor patients [2].
KDM6A is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 0 are open and 2 are closed. Of the trials that contain KDM6A status and malignant solid tumor as inclusion criteria, 2 are phase 1 (0 open) [3].
KDR +
KDR is altered in 3.28% of malignant solid tumor patients [2].
KDR is an inclusion eligibility criterion in 6 clinical trials for malignant solid tumor, of which 4 are open and 2 are closed. Of the trials that contain KDR status and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open) and 4 are phase 2 (3 open) [3].
KEAP1 +
KEAP1 is altered in 3.79% of malignant solid tumor patients [2].
KEAP1 is an inclusion eligibility criterion in 4 clinical trials for malignant solid tumor, of which 3 are open and 1 is closed. Of the trials that contain KEAP1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].
KIAA1217 +
KIAA1217 is altered in 0.1% of malignant solid tumor patients [2].
KIAA1217 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains KIAA1217 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
KIF5B +
KIF5B is altered in 0.28% of malignant solid tumor patients [2].
KIF5B is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains KIF5B status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
KIT +
KIT is altered in 3.15% of malignant solid tumor patients [2].
KIT is an inclusion eligibility criterion in 15 clinical trials for malignant solid tumor, of which 12 are open and 3 are closed. Of the trials that contain KIT status and malignant solid tumor as inclusion criteria, 6 are phase 1 (4 open), 1 is phase 1/phase 2 (1 open), and 8 are phase 2 (7 open) [3].
KMT2A +
KMT2A is altered in 4.65% of malignant solid tumor patients [2].
KMT2A is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
KMT2C +
KMT2C is altered in 6.2% of malignant solid tumor patients [2].
KMT2C is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains KMT2C status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
KMT2D +
KMT2D is altered in 10.18% of malignant solid tumor patients [2].
KMT2D is an inclusion eligibility criterion in 3 clinical trials for malignant solid tumor, of which 1 is open and 2 are closed. Of the trials that contain KMT2D status and malignant solid tumor as inclusion criteria, 3 are phase 1 (1 open) [3].
KRAS +
KRAS is altered in 17.89% of malignant solid tumor patients [2].
KRAS is an inclusion eligibility criterion in 74 clinical trials for malignant solid tumor, of which 51 are open and 23 are closed. Of the trials that contain KRAS status and malignant solid tumor as inclusion criteria, 41 are phase 1 (26 open), 23 are phase 1/phase 2 (18 open), and 10 are phase 2 (7 open) [3].
LRP5 +
LRP5 is altered in 0.03% of malignant solid tumor patients [2].
LRP5 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains LRP5 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
LRP6 +
LRP6 is altered in 0.01% of malignant solid tumor patients [2].
LRP6 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains LRP6 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
MAGI2 +
MAGI2 is altered in 0.93% of malignant solid tumor patients [2].
MAGI2 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains MAGI2 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
MAML1 +
MAML1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains MAML1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
MAP2K1 +
MAP2K1 is altered in 1.05% of malignant solid tumor patients [2].
MAP2K1 is an inclusion eligibility criterion in 19 clinical trials for malignant solid tumor, of which 16 are open and 3 are closed. Of the trials that contain MAP2K1 status and malignant solid tumor as inclusion criteria, 9 are phase 1 (8 open), 2 are phase 1/phase 2 (2 open), and 8 are phase 2 (6 open) [3].
MAP2K2 +
MAP2K2 is altered in 0.92% of malignant solid tumor patients [2].
MAP2K2 is an inclusion eligibility criterion in 17 clinical trials for malignant solid tumor, of which 15 are open and 2 are closed. Of the trials that contain MAP2K2 status and malignant solid tumor as inclusion criteria, 9 are phase 1 (8 open), 2 are phase 1/phase 2 (2 open), and 6 are phase 2 (5 open) [3].
MAP2K4 +
MAP2K4 is altered in 2.18% of malignant solid tumor patients [2].
MAP2K4 is an inclusion eligibility criterion in 15 clinical trials for malignant solid tumor, of which 13 are open and 2 are closed. Of the trials that contain MAP2K4 status and malignant solid tumor as inclusion criteria, 9 are phase 1 (8 open), 2 are phase 1/phase 2 (2 open), and 4 are phase 2 (3 open) [3].
MAP3K1 +
MAP3K1 is altered in 3.56% of malignant solid tumor patients [2].
MAP3K1 is an inclusion eligibility criterion in 16 clinical trials for malignant solid tumor, of which 13 are open and 3 are closed. Of the trials that contain MAP3K1 status and malignant solid tumor as inclusion criteria, 10 are phase 1 (8 open), 2 are phase 1/phase 2 (2 open), and 4 are phase 2 (3 open) [3].
MAPK1 +
MAPK1 is altered in 0.9% of malignant solid tumor patients [2].
MAPK1 is an inclusion eligibility criterion in 17 clinical trials for malignant solid tumor, of which 14 are open and 3 are closed. Of the trials that contain MAPK1 status and malignant solid tumor as inclusion criteria, 9 are phase 1 (8 open), 2 are phase 1/phase 2 (2 open), and 6 are phase 2 (4 open) [3].
MAPK3 +
MAPK3 is altered in 0.84% of malignant solid tumor patients [2].
MAPK3 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains MAPK3 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
MCL1 +
MCL1 is altered in 1.97% of malignant solid tumor patients [2].
MCL1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains MCL1 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (0 open) [3].
MCPH1 +
MCPH1 is altered in 0.04% of malignant solid tumor patients [2].
MCPH1 is an inclusion eligibility criterion in 16 clinical trials for malignant solid tumor, of which 12 are open and 4 are closed. Of the trials that contain MCPH1 status and malignant solid tumor as inclusion criteria, 5 are phase 1 (3 open), 5 are phase 1/phase 2 (3 open), and 6 are phase 2 (6 open) [3].
MDM2 +
MDM2 is altered in 3.54% of malignant solid tumor patients [2].
MDM2 is an inclusion eligibility criterion in 16 clinical trials for malignant solid tumor, of which 13 are open and 3 are closed. Of the trials that contain MDM2 status and malignant solid tumor as inclusion criteria, 9 are phase 1 (8 open), 4 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [3].
MDM4 +
MDM4 is altered in 1.35% of malignant solid tumor patients [2].
MDM4 is an inclusion eligibility criterion in 13 clinical trials for malignant solid tumor, of which 11 are open and 2 are closed. Of the trials that contain MDM4 status and malignant solid tumor as inclusion criteria, 7 are phase 1 (7 open), 4 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [3].
MECOM +
MECOM is altered in 1.73% of malignant solid tumor patients [2].
MECOM is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 1 is open and 1 is closed. Of the trials that contain MECOM status and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open) [3].
MED12 +
MED12 is altered in 3.77% of malignant solid tumor patients [2].
MED12 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains MED12 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
MERTK +
MERTK is altered in 3.76% of malignant solid tumor patients [2].
MERTK is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains MERTK status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
MET +
MET is altered in 2.83% of malignant solid tumor patients [2].
MET is an inclusion eligibility criterion in 26 clinical trials for malignant solid tumor, of which 13 are open and 13 are closed. Of the trials that contain MET status and malignant solid tumor as inclusion criteria, 12 are phase 1 (3 open), 6 are phase 1/phase 2 (3 open), and 8 are phase 2 (7 open) [3].
MLF1 +
MLF1 is altered in 0.14% of malignant solid tumor patients [2].
MLF1 is an inclusion eligibility criterion in 12 clinical trials for malignant solid tumor, of which 9 are open and 3 are closed. Of the trials that contain MLF1 status and malignant solid tumor as inclusion criteria, 7 are phase 1 (6 open), 4 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].
MLH1 +
MLH1 is altered in 1.38% of malignant solid tumor patients [2].
MLH1 is an inclusion eligibility criterion in 15 clinical trials for malignant solid tumor, of which 13 are open and 2 are closed. Of the trials that contain MLH1 status and malignant solid tumor as inclusion criteria, 6 are phase 1 (6 open), 4 are phase 1/phase 2 (2 open), and 5 are phase 2 (5 open) [3].
MLH3 +
MLH3 is altered in 3.07% of malignant solid tumor patients [2].
MLH3 is an inclusion eligibility criterion in 13 clinical trials for malignant solid tumor, of which 11 are open and 2 are closed. Of the trials that contain MLH3 status and malignant solid tumor as inclusion criteria, 6 are phase 1 (6 open), 4 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [3].
MLLT1 +
MLLT1 is altered in 0.12% of malignant solid tumor patients [2].
MLLT1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains MLLT1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
MLLT10 +
MLLT10 is altered in 0.28% of malignant solid tumor patients [2].
MLLT10 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains MLLT10 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
MLLT3 +
MLLT3 is altered in 0.21% of malignant solid tumor patients [2].
MLLT3 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains MLLT3 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
MLLT4 +
MLLT4 is altered in 0.4% of malignant solid tumor patients [2].
MLLT4 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains MLLT4 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
MRE11A +
MRE11A is altered in 1.4% of malignant solid tumor patients [2].
MRE11A is an inclusion eligibility criterion in 29 clinical trials for malignant solid tumor, of which 24 are open and 5 are closed. Of the trials that contain MRE11A status and malignant solid tumor as inclusion criteria, 12 are phase 1 (10 open), 7 are phase 1/phase 2 (4 open), and 10 are phase 2 (10 open) [3].
MSH2 +
MSH2 is altered in 2.1% of malignant solid tumor patients [2].
MSH2 is an inclusion eligibility criterion in 17 clinical trials for malignant solid tumor, of which 14 are open and 3 are closed. Of the trials that contain MSH2 status and malignant solid tumor as inclusion criteria, 8 are phase 1 (7 open), 4 are phase 1/phase 2 (2 open), and 5 are phase 2 (5 open) [3].
MSH3 +
MSH3 is altered in 2.37% of malignant solid tumor patients [2].
MSH3 is an inclusion eligibility criterion in 12 clinical trials for malignant solid tumor, of which 10 are open and 2 are closed. Of the trials that contain MSH3 status and malignant solid tumor as inclusion criteria, 6 are phase 1 (6 open), 4 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [3].
MSH6 +
MSH6 is altered in 2.65% of malignant solid tumor patients [2].
MSH6 is an inclusion eligibility criterion in 15 clinical trials for malignant solid tumor, of which 12 are open and 3 are closed. Of the trials that contain MSH6 status and malignant solid tumor as inclusion criteria, 7 are phase 1 (6 open), 4 are phase 1/phase 2 (2 open), and 4 are phase 2 (4 open) [3].
MST1R +
MST1R is altered in 1.64% of malignant solid tumor patients [2].
MST1R is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains MST1R status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
MTAP +
MTAP is altered in 1.16% of malignant solid tumor patients [2].
MTAP is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains MTAP status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
MTOR +
MTOR is altered in 3.61% of malignant solid tumor patients [2].
MTOR is an inclusion eligibility criterion in 21 clinical trials for malignant solid tumor, of which 17 are open and 4 are closed. Of the trials that contain MTOR status and malignant solid tumor as inclusion criteria, 7 are phase 1 (4 open), 3 are phase 1/phase 2 (3 open), and 11 are phase 2 (10 open) [3].
MUTYH +
MUTYH is altered in 1.13% of malignant solid tumor patients [2].
MUTYH is an inclusion eligibility criterion in 12 clinical trials for malignant solid tumor, of which 10 are open and 2 are closed. Of the trials that contain MUTYH status and malignant solid tumor as inclusion criteria, 6 are phase 1 (6 open), 4 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [3].
MYC +
MYC is altered in 4.85% of malignant solid tumor patients [2].
MYC is an inclusion eligibility criterion in 9 clinical trials for malignant solid tumor, of which 4 are open and 5 are closed. Of the trials that contain MYC status and malignant solid tumor as inclusion criteria, 4 are phase 1 (2 open), 2 are phase 1/phase 2 (0 open), and 3 are phase 2 (2 open) [3].
MYCN +
MYCN is altered in 1.51% of malignant solid tumor patients [2].
MYCN is an inclusion eligibility criterion in 4 clinical trials for malignant solid tumor, of which 2 are open and 2 are closed. Of the trials that contain MYCN status and malignant solid tumor as inclusion criteria, 4 are phase 1 (2 open) [3].
NBN +
NBN is altered in 2.42% of malignant solid tumor patients [2].
NBN is an inclusion eligibility criterion in 32 clinical trials for malignant solid tumor, of which 26 are open and 6 are closed. Of the trials that contain NBN status and malignant solid tumor as inclusion criteria, 12 are phase 1 (9 open), 7 are phase 1/phase 2 (4 open), and 13 are phase 2 (13 open) [3].
NCOA4 +
NCOA4 is altered in 0.09% of malignant solid tumor patients [2].
NCOA4 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains NCOA4 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
NCSTN +
NCSTN is altered in 2.09% of malignant solid tumor patients [2].
NCSTN is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains NCSTN status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
NF1 +
NF1 is altered in 7.15% of malignant solid tumor patients [2].
NF1 is an inclusion eligibility criterion in 27 clinical trials for malignant solid tumor, of which 24 are open and 3 are closed. Of the trials that contain NF1 status and malignant solid tumor as inclusion criteria, 14 are phase 1 (12 open), 4 are phase 1/phase 2 (4 open), and 9 are phase 2 (8 open) [3].
NF2 +
NF2 is altered in 1.87% of malignant solid tumor patients [2].
NF2 is an inclusion eligibility criterion in 3 clinical trials for malignant solid tumor, of which 2 are open and 1 is closed. Of the trials that contain NF2 status and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [3].
NFE2L2 +
NFE2L2 is altered in 1.82% of malignant solid tumor patients [2].
NFE2L2 is an inclusion eligibility criterion in 4 clinical trials for malignant solid tumor, of which 4 are open and 0 are closed. Of the trials that contain NFE2L2 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open) [3].
NOTCH1 +
NOTCH1 is altered in 4.66% of malignant solid tumor patients [2].
NOTCH1 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 0 are open and 2 are closed. Of the trials that contain NOTCH1 status and malignant solid tumor as inclusion criteria, 2 are phase 1 (0 open) [3].
NOTCH2 +
NOTCH2 is altered in 3.78% of malignant solid tumor patients [2].
NOTCH2 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 0 are open and 2 are closed. Of the trials that contain NOTCH2 status and malignant solid tumor as inclusion criteria, 2 are phase 1 (0 open) [3].
NOTCH3 +
NOTCH3 is altered in 4.13% of malignant solid tumor patients [2].
NOTCH3 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains NOTCH3 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
NOTCH4 +
NOTCH4 is altered in 3.12% of malignant solid tumor patients [2].
NOTCH4 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains NOTCH4 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
NPM1 +
NPM1 is altered in 0.52% of malignant solid tumor patients [2].
NPM1 is an inclusion eligibility criterion in 13 clinical trials for malignant solid tumor, of which 10 are open and 3 are closed. Of the trials that contain NPM1 status and malignant solid tumor as inclusion criteria, 7 are phase 1 (6 open), 4 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [3].
NR4A3 +
NR4A3 is altered in 0.05% of malignant solid tumor patients [2].
NR4A3 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains NR4A3 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
NRAS +
NRAS is altered in 2.83% of malignant solid tumor patients [2].
NRAS is an inclusion eligibility criterion in 39 clinical trials for malignant solid tumor, of which 27 are open and 12 are closed. Of the trials that contain NRAS status and malignant solid tumor as inclusion criteria, 21 are phase 1 (13 open), 11 are phase 1/phase 2 (8 open), and 7 are phase 2 (6 open) [3].
NRG1 +
NRG1 is altered in 0.77% of malignant solid tumor patients [2].
NRG1 is an inclusion eligibility criterion in 5 clinical trials for malignant solid tumor, of which 5 are open and 0 are closed. Of the trials that contain NRG1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].
NRIP3 +
NRIP3 is altered in 0.08% of malignant solid tumor patients [2].
NRIP3 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains NRIP3 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
NSD1 +
NSD1 is altered in 3.4% of malignant solid tumor patients [2].
NSD1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains NSD1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
NTRK1 +
NTRK1 is altered in 2.96% of malignant solid tumor patients [2].
NTRK1 is an inclusion eligibility criterion in 26 clinical trials for malignant solid tumor, of which 20 are open and 6 are closed. Of the trials that contain NTRK1 status and malignant solid tumor as inclusion criteria, 7 are phase 1 (2 open), 7 are phase 1/phase 2 (6 open), and 12 are phase 2 (12 open) [3].
Entrectinib and larotrectinib have evidence of efficacy in patients with NTRK1 mutation in malignant solid tumor [3].
NTRK2 +
NTRK2 is altered in 1.55% of malignant solid tumor patients [2].
NTRK2 is an inclusion eligibility criterion in 25 clinical trials for malignant solid tumor, of which 19 are open and 6 are closed. Of the trials that contain NTRK2 status and malignant solid tumor as inclusion criteria, 6 are phase 1 (1 open), 7 are phase 1/phase 2 (6 open), and 12 are phase 2 (12 open) [3].
Entrectinib and larotrectinib have evidence of efficacy in patients with NTRK2 mutation in malignant solid tumor [3].
NTRK3 +
NTRK3 is altered in 3.03% of malignant solid tumor patients [2].
NTRK3 is an inclusion eligibility criterion in 26 clinical trials for malignant solid tumor, of which 20 are open and 6 are closed. Of the trials that contain NTRK3 status and malignant solid tumor as inclusion criteria, 6 are phase 1 (1 open), 7 are phase 1/phase 2 (6 open), and 13 are phase 2 (13 open) [3].
Entrectinib and larotrectinib have evidence of efficacy in patients with NTRK3 mutation in malignant solid tumor [3].
NUP214 +
NUP214 is altered in 0.24% of malignant solid tumor patients [2].
NUP214 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains NUP214 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
NUTM1 +
NUTM1 is altered in 0.4% of malignant solid tumor patients [2].
NUTM1 is an inclusion eligibility criterion in 3 clinical trials for malignant solid tumor, of which 0 are open and 3 are closed. Of the trials that contain NUTM1 status and malignant solid tumor as inclusion criteria, 3 are phase 1 (0 open) [3].
PALB2 +
PALB2 is altered in 1.99% of malignant solid tumor patients [2].
PALB2 is an inclusion eligibility criterion in 35 clinical trials for malignant solid tumor, of which 29 are open and 6 are closed. Of the trials that contain PALB2 status and malignant solid tumor as inclusion criteria, 15 are phase 1 (12 open), 8 are phase 1/phase 2 (5 open), and 12 are phase 2 (12 open) [3].
PARP1 +
PARP1 is altered in 1.47% of malignant solid tumor patients [2].
PARP1 is an inclusion eligibility criterion in 14 clinical trials for malignant solid tumor, of which 12 are open and 2 are closed. Of the trials that contain PARP1 status and malignant solid tumor as inclusion criteria, 7 are phase 1 (7 open), 4 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [3].
PARP2 +
PARP2 is altered in 0.93% of malignant solid tumor patients [2].
PARP2 is an inclusion eligibility criterion in 13 clinical trials for malignant solid tumor, of which 11 are open and 2 are closed. Of the trials that contain PARP2 status and malignant solid tumor as inclusion criteria, 6 are phase 1 (6 open), 4 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [3].
PBX1 +
PBX1 is altered in 0.17% of malignant solid tumor patients [2].
PBX1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PBX1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
PCNA +
PCNA is altered in 0.27% of malignant solid tumor patients [2].
PCNA is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PCNA status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
PDGFB +
PDGFB is altered in 0.07% of malignant solid tumor patients [2].
PDGFB is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PDGFB status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
PDGFRA +
PDGFRA is altered in 3.06% of malignant solid tumor patients [2].
PDGFRA is an inclusion eligibility criterion in 25 clinical trials for malignant solid tumor, of which 20 are open and 5 are closed. Of the trials that contain PDGFRA status and malignant solid tumor as inclusion criteria, 9 are phase 1 (6 open), 4 are phase 1/phase 2 (4 open), and 12 are phase 2 (10 open) [3].
PDGFRB +
PDGFRB is altered in 2.39% of malignant solid tumor patients [2].
PDGFRB is an inclusion eligibility criterion in 4 clinical trials for malignant solid tumor, of which 3 are open and 1 is closed. Of the trials that contain PDGFRB status and malignant solid tumor as inclusion criteria, 4 are phase 2 (3 open) [3].
PIK3C2B +
PIK3C2B is altered in 4.16% of malignant solid tumor patients [2].
PIK3C2B is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains PIK3C2B status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
PIK3C2G +
PIK3C2G is altered in 3.27% of malignant solid tumor patients [2].
PIK3C2G is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PIK3C2G status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
PIK3C3 +
PIK3C3 is altered in 1.32% of malignant solid tumor patients [2].
PIK3C3 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PIK3C3 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
PIK3CA +
PIK3CA is altered in 13.98% of malignant solid tumor patients [2].
PIK3CA is an inclusion eligibility criterion in 37 clinical trials for malignant solid tumor, of which 26 are open and 11 are closed. Of the trials that contain PIK3CA status and malignant solid tumor as inclusion criteria, 18 are phase 1 (10 open), 6 are phase 1/phase 2 (4 open), 12 are phase 2 (11 open), and 1 is phase 4 (1 open) [3].
PIK3CB +
PIK3CB is altered in 1.67% of malignant solid tumor patients [2].
PIK3CB is an inclusion eligibility criterion in 5 clinical trials for malignant solid tumor, of which 3 are open and 2 are closed. Of the trials that contain PIK3CB status and malignant solid tumor as inclusion criteria, 4 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
PIK3CD +
PIK3CD is altered in 1.76% of malignant solid tumor patients [2].
PIK3CD is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PIK3CD status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
PIK3CG +
PIK3CG is altered in 3.0% of malignant solid tumor patients [2].
PIK3CG is an inclusion eligibility criterion in 14 clinical trials for malignant solid tumor, of which 11 are open and 3 are closed. Of the trials that contain PIK3CG status and malignant solid tumor as inclusion criteria, 6 are phase 1 (4 open), 3 are phase 1/phase 2 (3 open), and 5 are phase 2 (4 open) [3].
PIK3R1 +
PIK3R1 is altered in 3.62% of malignant solid tumor patients [2].
PIK3R1 is an inclusion eligibility criterion in 16 clinical trials for malignant solid tumor, of which 12 are open and 4 are closed. Of the trials that contain PIK3R1 status and malignant solid tumor as inclusion criteria, 7 are phase 1 (4 open), 3 are phase 1/phase 2 (3 open), and 6 are phase 2 (5 open) [3].
PIK3R2 +
PIK3R2 is altered in 1.42% of malignant solid tumor patients [2].
PIK3R2 is an inclusion eligibility criterion in 14 clinical trials for malignant solid tumor, of which 11 are open and 3 are closed. Of the trials that contain PIK3R2 status and malignant solid tumor as inclusion criteria, 6 are phase 1 (4 open), 3 are phase 1/phase 2 (3 open), and 5 are phase 2 (4 open) [3].
PIK3R3 +
PIK3R3 is altered in 0.69% of malignant solid tumor patients [2].
PIK3R3 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PIK3R3 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
PMS1 +
PMS1 is altered in 1.39% of malignant solid tumor patients [2].
PMS1 is an inclusion eligibility criterion in 13 clinical trials for malignant solid tumor, of which 11 are open and 2 are closed. Of the trials that contain PMS1 status and malignant solid tumor as inclusion criteria, 6 are phase 1 (6 open), 4 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [3].
PMS2 +
PMS2 is altered in 1.74% of malignant solid tumor patients [2].
PMS2 is an inclusion eligibility criterion in 14 clinical trials for malignant solid tumor, of which 12 are open and 2 are closed. Of the trials that contain PMS2 status and malignant solid tumor as inclusion criteria, 6 are phase 1 (6 open), 4 are phase 1/phase 2 (2 open), and 4 are phase 2 (4 open) [3].
POLD1 +
POLD1 is altered in 2.56% of malignant solid tumor patients [2].
POLD1 is an inclusion eligibility criterion in 9 clinical trials for malignant solid tumor, of which 9 are open and 0 are closed. Of the trials that contain POLD1 status and malignant solid tumor as inclusion criteria, 3 are phase 1 (3 open) and 6 are phase 2 (6 open) [3].
POLE +
POLE is altered in 3.65% of malignant solid tumor patients [2].
POLE is an inclusion eligibility criterion in 20 clinical trials for malignant solid tumor, of which 18 are open and 2 are closed. Of the trials that contain POLE status and malignant solid tumor as inclusion criteria, 8 are phase 1 (8 open), 4 are phase 1/phase 2 (2 open), and 8 are phase 2 (8 open) [3].
POLQ +
POLQ is altered in 6.07% of malignant solid tumor patients [2].
POLQ is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains POLQ status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
PPFIBP2 +
PPFIBP2 is altered in 0.24% of malignant solid tumor patients [2].
PPFIBP2 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PPFIBP2 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
PPM1D +
PPM1D is altered in 2.16% of malignant solid tumor patients [2].
PPM1D is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PPM1D status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
PPP2R1A +
PPP2R1A is altered in 2.02% of malignant solid tumor patients [2].
PPP2R1A is an inclusion eligibility criterion in 12 clinical trials for malignant solid tumor, of which 10 are open and 2 are closed. Of the trials that contain PPP2R1A status and malignant solid tumor as inclusion criteria, 6 are phase 1 (6 open), 4 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [3].
PPP2R2A +
PPP2R2A is altered in 0.57% of malignant solid tumor patients [2].
PPP2R2A is an inclusion eligibility criterion in 16 clinical trials for malignant solid tumor, of which 14 are open and 2 are closed. Of the trials that contain PPP2R2A status and malignant solid tumor as inclusion criteria, 8 are phase 1 (8 open), 5 are phase 1/phase 2 (3 open), and 3 are phase 2 (3 open) [3].
PRKAR1A +
PRKAR1A is altered in 1.16% of malignant solid tumor patients [2].
PRKAR1A is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PRKAR1A status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
PRKCA +
PRKCA is altered in 0.09% of malignant solid tumor patients [2].
PRKCA is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PRKCA status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PRKCB +
PRKCB is altered in 0.06% of malignant solid tumor patients [2].
PRKCB is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PRKCB status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PRKCD +
PRKCD is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PRKCD status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PRKCE +
PRKCE is altered in 0.16% of malignant solid tumor patients [2].
PRKCE is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PRKCE status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PRKCG +
PRKCG is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PRKCG status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PRKCI +
PRKCI is altered in 1.95% of malignant solid tumor patients [2].
PRKCI is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PRKCI status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PRKCQ +
PRKCQ is altered in 5.16% of malignant solid tumor patients [2].
PRKCQ is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PRKCQ status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PRKCZ +
PRKCZ is altered in 0.49% of malignant solid tumor patients [2].
PRKCZ is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PRKCZ status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PRKDC +
PRKDC is altered in 8.4% of malignant solid tumor patients [2].
PRKDC is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PRKDC status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
PTCH1 +
PTCH1 is altered in 3.0% of malignant solid tumor patients [2].
PTCH1 is an inclusion eligibility criterion in 4 clinical trials for malignant solid tumor, of which 3 are open and 1 is closed. Of the trials that contain PTCH1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (3 open) [3].
PTEN +
PTEN is altered in 8.13% of malignant solid tumor patients [2].
PTEN is an inclusion eligibility criterion in 48 clinical trials for malignant solid tumor, of which 36 are open and 12 are closed. Of the trials that contain PTEN status and malignant solid tumor as inclusion criteria, 20 are phase 1 (12 open), 11 are phase 1/phase 2 (8 open), 16 are phase 2 (15 open), and 1 is phase 4 (1 open) [3].
PTPN11 +
PTPN11 is altered in 1.2% of malignant solid tumor patients [2].
PTPN11 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains PTPN11 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
RAD50 +
RAD50 is altered in 1.63% of malignant solid tumor patients [2].
RAD50 is an inclusion eligibility criterion in 27 clinical trials for malignant solid tumor, of which 22 are open and 5 are closed. Of the trials that contain RAD50 status and malignant solid tumor as inclusion criteria, 11 are phase 1 (9 open), 7 are phase 1/phase 2 (4 open), and 9 are phase 2 (9 open) [3].
RAD51 +
RAD51 is altered in 0.69% of malignant solid tumor patients [2].
RAD51 is an inclusion eligibility criterion in 31 clinical trials for malignant solid tumor, of which 25 are open and 6 are closed. Of the trials that contain RAD51 status and malignant solid tumor as inclusion criteria, 12 are phase 1 (9 open), 7 are phase 1/phase 2 (4 open), and 12 are phase 2 (12 open) [3].
RAD51B +
RAD51B is altered in 0.44% of malignant solid tumor patients [2].
RAD51B is an inclusion eligibility criterion in 31 clinical trials for malignant solid tumor, of which 25 are open and 6 are closed. Of the trials that contain RAD51B status and malignant solid tumor as inclusion criteria, 14 are phase 1 (11 open), 7 are phase 1/phase 2 (4 open), and 10 are phase 2 (10 open) [3].
RAD51C +
RAD51C is altered in 1.34% of malignant solid tumor patients [2].
RAD51C is an inclusion eligibility criterion in 36 clinical trials for malignant solid tumor, of which 30 are open and 6 are closed. Of the trials that contain RAD51C status and malignant solid tumor as inclusion criteria, 14 are phase 1 (11 open), 8 are phase 1/phase 2 (5 open), and 14 are phase 2 (14 open) [3].
RAD51D +
RAD51D is altered in 0.65% of malignant solid tumor patients [2].
RAD51D is an inclusion eligibility criterion in 35 clinical trials for malignant solid tumor, of which 29 are open and 6 are closed. Of the trials that contain RAD51D status and malignant solid tumor as inclusion criteria, 14 are phase 1 (11 open), 8 are phase 1/phase 2 (5 open), and 13 are phase 2 (13 open) [3].
RAD54L +
RAD54L is altered in 0.81% of malignant solid tumor patients [2].
RAD54L is an inclusion eligibility criterion in 31 clinical trials for malignant solid tumor, of which 25 are open and 6 are closed. Of the trials that contain RAD54L status and malignant solid tumor as inclusion criteria, 14 are phase 1 (11 open), 7 are phase 1/phase 2 (4 open), and 10 are phase 2 (10 open) [3].
RAF1 +
RAF1 is altered in 1.33% of malignant solid tumor patients [2].
RAF1 is an inclusion eligibility criterion in 19 clinical trials for malignant solid tumor, of which 16 are open and 3 are closed. Of the trials that contain RAF1 status and malignant solid tumor as inclusion criteria, 10 are phase 1 (9 open), 2 are phase 1/phase 2 (2 open), and 7 are phase 2 (5 open) [3].
RASA1 +
RASA1 is altered in 2.03% of malignant solid tumor patients [2].
RASA1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains RASA1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
RB1 +
RB1 is altered in 5.49% of malignant solid tumor patients [2].
RB1 is an inclusion eligibility criterion in 7 clinical trials for malignant solid tumor, of which 4 are open and 3 are closed. Of the trials that contain RB1 status and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 4 are phase 2 (3 open) [3].
RET +
RET is altered in 2.84% of malignant solid tumor patients [2].
RET is an inclusion eligibility criterion in 20 clinical trials for malignant solid tumor, of which 20 are open and 0 are closed. Of the trials that contain RET status and malignant solid tumor as inclusion criteria, 2 are phase 1 (2 open), 7 are phase 1/phase 2 (7 open), 9 are phase 2 (9 open), 1 is phase 4 (1 open), and 1 is no phase specified (1 open) [3].
RFC1 +
RFC1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains RFC1 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
RFC2 +
RFC2 is altered in 0.27% of malignant solid tumor patients [2].
RFC2 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains RFC2 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
RFC3 +
RFC3 is altered in 0.01% of malignant solid tumor patients [2].
RFC3 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains RFC3 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
RFC4 +
RFC4 is altered in 0.01% of malignant solid tumor patients [2].
RFC4 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains RFC4 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
RFC5 +
RFC5 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains RFC5 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
RHEB +
RHEB is altered in 0.4% of malignant solid tumor patients [2].
RHEB is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains RHEB status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
RICTOR +
RICTOR is altered in 2.6% of malignant solid tumor patients [2].
RICTOR is an inclusion eligibility criterion in 15 clinical trials for malignant solid tumor, of which 11 are open and 4 are closed. Of the trials that contain RICTOR status and malignant solid tumor as inclusion criteria, 5 are phase 1 (3 open), 3 are phase 1/phase 2 (3 open), and 7 are phase 2 (5 open) [3].
RNF43 +
RNF43 is altered in 3.54% of malignant solid tumor patients [2].
RNF43 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 1 is open and 1 is closed. Of the trials that contain RNF43 status and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open) [3].
ROS1 +
ROS1 is altered in 4.56% of malignant solid tumor patients [2].
ROS1 is an inclusion eligibility criterion in 19 clinical trials for malignant solid tumor, of which 17 are open and 2 are closed. Of the trials that contain ROS1 status and malignant solid tumor as inclusion criteria, 5 are phase 1 (3 open), 3 are phase 1/phase 2 (3 open), and 11 are phase 2 (11 open) [3].
RPA1 +
RPA1 is altered in 1.46% of malignant solid tumor patients [2].
RPA1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains RPA1 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
RPA2 +
RPA2 is altered in 0.27% of malignant solid tumor patients [2].
RPA2 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
RPA3 +
RPA3 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains RPA3 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
RPA4 +
RPA4 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains RPA4 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
RPN1 +
RPN1 is altered in 0.2% of malignant solid tumor patients [2].
RPN1 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 1 is open and 1 is closed. Of the trials that contain RPN1 status and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open) [3].
RPTOR +
RPTOR is altered in 2.31% of malignant solid tumor patients [2].
RPTOR is an inclusion eligibility criterion in 13 clinical trials for malignant solid tumor, of which 10 are open and 3 are closed. Of the trials that contain RPTOR status and malignant solid tumor as inclusion criteria, 5 are phase 1 (3 open), 3 are phase 1/phase 2 (3 open), and 5 are phase 2 (4 open) [3].
RSPO1 +
RSPO1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains RSPO1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
RUFY1 +
RUFY1 is altered in 0.05% of malignant solid tumor patients [2].
RUFY1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains RUFY1 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
RUNX1 +
RUNX1 is altered in 1.98% of malignant solid tumor patients [2].
RUNX1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
SDHA +
SDHA is altered in 2.85% of malignant solid tumor patients [2].
SDHA is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 1 is open and 1 is closed. Of the trials that contain SDHA status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
SDHAF2 +
SDHAF2 is altered in 0.4% of malignant solid tumor patients [2].
SDHAF2 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains SDHAF2 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
SDHB +
SDHB is altered in 0.56% of malignant solid tumor patients [2].
SDHB is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 1 is open and 1 is closed. Of the trials that contain SDHB status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
SDHC +
SDHC is altered in 1.6% of malignant solid tumor patients [2].
SDHC is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 1 is open and 1 is closed. Of the trials that contain SDHC status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
SDHD +
SDHD is altered in 0.45% of malignant solid tumor patients [2].
SDHD is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 1 is open and 1 is closed. Of the trials that contain SDHD status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
SETD2 +
SETD2 is altered in 4.88% of malignant solid tumor patients [2].
SETD2 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 1 is open and 1 is closed. Of the trials that contain SETD2 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
SLX4 +
SLX4 is altered in 3.18% of malignant solid tumor patients [2].
SLX4 is an inclusion eligibility criterion in 26 clinical trials for malignant solid tumor, of which 21 are open and 5 are closed. Of the trials that contain SLX4 status and malignant solid tumor as inclusion criteria, 11 are phase 1 (9 open), 7 are phase 1/phase 2 (4 open), and 8 are phase 2 (8 open) [3].
SMARCA2 +
SMARCA2 is altered in 3.33% of malignant solid tumor patients [2].
SMARCA2 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains SMARCA2 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
SMARCA4 +
SMARCA4 is altered in 4.95% of malignant solid tumor patients [2].
SMARCA4 is an inclusion eligibility criterion in 6 clinical trials for malignant solid tumor, of which 4 are open and 2 are closed. Of the trials that contain SMARCA4 status and malignant solid tumor as inclusion criteria, 3 are phase 1 (1 open) and 3 are phase 2 (3 open) [3].
SMARCB1 +
SMARCB1 is altered in 1.15% of malignant solid tumor patients [2].
SMARCB1 is an inclusion eligibility criterion in 18 clinical trials for malignant solid tumor, of which 15 are open and 3 are closed. Of the trials that contain SMARCB1 status and malignant solid tumor as inclusion criteria, 9 are phase 1 (8 open), 4 are phase 1/phase 2 (2 open), and 5 are phase 2 (5 open) [3].
SMO +
SMO is altered in 1.75% of malignant solid tumor patients [2].
SMO is an inclusion eligibility criterion in 3 clinical trials for malignant solid tumor, of which 3 are open and 0 are closed. Of the trials that contain SMO status and malignant solid tumor as inclusion criteria, 3 are phase 2 (3 open) [3].
SOS1 +
SOS1 is altered in 1.87% of malignant solid tumor patients [2].
SOS1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains SOS1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
SOX9 +
SOX9 is altered in 2.94% of malignant solid tumor patients [2].
SOX9 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains SOX9 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
SRC +
SRC is altered in 1.18% of malignant solid tumor patients [2].
SRC is an inclusion eligibility criterion in 16 clinical trials for malignant solid tumor, of which 14 are open and 2 are closed. Of the trials that contain SRC status and malignant solid tumor as inclusion criteria, 9 are phase 1 (8 open), 2 are phase 1/phase 2 (2 open), and 5 are phase 2 (4 open) [3].
SS18 +
SS18 is altered in 0.46% of malignant solid tumor patients [2].
SS18 is an inclusion eligibility criterion in 4 clinical trials for malignant solid tumor, of which 3 are open and 1 is closed. Of the trials that contain SS18 status and malignant solid tumor as inclusion criteria, 3 are phase 1 (2 open) and 1 is phase 2 (1 open) [3].
SSBP1 +
SSBP1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains SSBP1 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
SSX1 +
SSX1 is altered in 0.08% of malignant solid tumor patients [2].
SSX1 is an inclusion eligibility criterion in 3 clinical trials for malignant solid tumor, of which 2 are open and 1 is closed. Of the trials that contain SSX1 status and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [3].
SSX2 +
SSX2 is altered in 0.07% of malignant solid tumor patients [2].
SSX2 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 1 is open and 1 is closed. Of the trials that contain SSX2 status and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open) [3].
SSX2B +
SSX2B is altered in 0.05% of malignant solid tumor patients [2].
SSX2B is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains SSX2B status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
SSX4 +
SSX4 is altered in 0.13% of malignant solid tumor patients [2].
SSX4 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 1 is open and 1 is closed. Of the trials that contain SSX4 status and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open) [3].
STAG2 +
STAG2 is altered in 2.66% of malignant solid tumor patients [2].
STAG2 is an inclusion eligibility criterion in 13 clinical trials for malignant solid tumor, of which 10 are open and 3 are closed. Of the trials that contain STAG2 status and malignant solid tumor as inclusion criteria, 7 are phase 1 (6 open), 4 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [3].
STAT1 +
STAT1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains STAT1 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (0 open) [3].
STAT2 +
STAT2 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains STAT2 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (0 open) [3].
STAT3 +
STAT3 is altered in 1.29% of malignant solid tumor patients [2].
STAT3 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains STAT3 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (0 open) [3].
STAT4 +
STAT4 is altered in 1.94% of malignant solid tumor patients [2].
STAT4 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains STAT4 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (0 open) [3].
STAT5A +
STAT5A is altered in 0.98% of malignant solid tumor patients [2].
STAT5A is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains STAT5A status and malignant solid tumor as inclusion criteria, 1 is phase 2 (0 open) [3].
STAT5B +
STAT5B is altered in 0.87% of malignant solid tumor patients [2].
STAT5B is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains STAT5B status and malignant solid tumor as inclusion criteria, 1 is phase 2 (0 open) [3].
STAT6 +
STAT6 is altered in 0.74% of malignant solid tumor patients [2].
STAT6 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains STAT6 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (0 open) [3].
STK11 +
STK11 is altered in 3.31% of malignant solid tumor patients [2].
STK11 is an inclusion eligibility criterion in 17 clinical trials for malignant solid tumor, of which 14 are open and 3 are closed. Of the trials that contain STK11 status and malignant solid tumor as inclusion criteria, 7 are phase 1 (6 open), 6 are phase 1/phase 2 (4 open), and 4 are phase 2 (4 open) [3].
TAF1 +
TAF1 is altered in 3.15% of malignant solid tumor patients [2].
TAF1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains TAF1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
TBX3 +
TBX3 is altered in 3.15% of malignant solid tumor patients [2].
TBX3 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains TBX3 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
TCF3 +
TCF3 is altered in 1.76% of malignant solid tumor patients [2].
TCF3 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains TCF3 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
TEK +
TEK is altered in 1.73% of malignant solid tumor patients [2].
TEK is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains TEK status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
TET2 +
TET2 is altered in 3.54% of malignant solid tumor patients [2].
TET2 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 1 is open and 1 is closed. Of the trials that contain TET2 status and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open) [3].
TFE3 +
TFE3 is altered in 0.54% of malignant solid tumor patients [2].
TFE3 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 1 is open and 1 is closed. Of the trials that contain TFE3 status and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open) [3].
TFEB +
TFEB is altered in 0.84% of malignant solid tumor patients [2].
TFEB is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains TFEB status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
TFG +
TFG is altered in 0.21% of malignant solid tumor patients [2].
TFG is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains TFG status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
TP53 +
TP53 is altered in 43.65% of malignant solid tumor patients [2].
TP53 is an inclusion eligibility criterion in 14 clinical trials for malignant solid tumor, of which 8 are open and 6 are closed. Of the trials that contain TP53 status and malignant solid tumor as inclusion criteria, 6 are phase 1 (3 open), 5 are phase 1/phase 2 (3 open), and 3 are phase 2 (2 open) [3].
TRIM27 +
TRIM27 is altered in 0.12% of malignant solid tumor patients [2].
TRIM27 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains TRIM27 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
TSC1 +
TSC1 is altered in 2.35% of malignant solid tumor patients [2].
TSC1 is an inclusion eligibility criterion in 20 clinical trials for malignant solid tumor, of which 14 are open and 6 are closed. Of the trials that contain TSC1 status and malignant solid tumor as inclusion criteria, 6 are phase 1 (3 open), 3 are phase 1/phase 2 (3 open), and 11 are phase 2 (8 open) [3].
TSC2 +
TSC2 is altered in 3.6% of malignant solid tumor patients [2].
TSC2 is an inclusion eligibility criterion in 20 clinical trials for malignant solid tumor, of which 14 are open and 6 are closed. Of the trials that contain TSC2 status and malignant solid tumor as inclusion criteria, 6 are phase 1 (3 open), 3 are phase 1/phase 2 (3 open), and 11 are phase 2 (8 open) [3].
TYRO3 +
TYRO3 is altered in 0.04% of malignant solid tumor patients [2].
TYRO3 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains TYRO3 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
UGT1A1 +
UGT1A1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains UGT1A1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
VEGFA +
VEGFA is altered in 1.16% of malignant solid tumor patients [2].
VEGFA is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains VEGFA status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
VEGFB +
VEGFB is altered in 0.56% of malignant solid tumor patients [2].
VEGFB is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
VEGFC +
VEGFC is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains VEGFC status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
VHL +
VHL is altered in 1.54% of malignant solid tumor patients [2].
VHL is an inclusion eligibility criterion in 3 clinical trials for malignant solid tumor, of which 3 are open and 0 are closed. Of the trials that contain VHL status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].
WNT1 +
WNT1 is altered in 0.0% of malignant solid tumor patients [2].
WNT1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains WNT1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
WRN +
WRN is altered in 3.36% of malignant solid tumor patients [2].
WRN is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains WRN status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
WT1 +
WT1 is altered in 1.76% of malignant solid tumor patients [2].
WT1 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain WT1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
XPO1 +
XPO1 is altered in 1.19% of malignant solid tumor patients [2].
XPO1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains XPO1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
XRCC1 +
XRCC1 is altered in 1.8% of malignant solid tumor patients [2].
XRCC1 is an inclusion eligibility criterion in 13 clinical trials for malignant solid tumor, of which 11 are open and 2 are closed. Of the trials that contain XRCC1 status and malignant solid tumor as inclusion criteria, 7 are phase 1 (7 open), 4 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [3].
XRCC2 +
XRCC2 is altered in 0.63% of malignant solid tumor patients [2].
XRCC2 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains XRCC2 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
